.Pharmacolibrary.Drugs.ATC.V.V10XX02 .Pharmacolibrary.Drugs.ATC.V.V10XX02| name: | IbritumomabTiuxetan90y |
| ATC code: | V10XX02 | route: | intravenous |
| n-compartments | 2 |
Ibritumomab tiuxetan (90Y) is a radiolabeled monoclonal antibody targeting the CD20 antigen on B cells. It is used as a radioimmunotherapy for treatment of certain types of non-Hodgkin's lymphoma, including relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Its use is currently limited and it is not widely approved or available in many countries.
Pharmacokinetic parameters are primarily derived from adult cancer patients with non-Hodgkin's lymphoma, both sexes, aged 18-80, without major renal or hepatic insufficiency.